---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-011962"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2025-05-22T23:59:59+00:00"
generated_at: "2026-05-20T18:15:31.671155+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Evofem signs exclusive SOLOSEC license for UAE, Kuwait, Saudi Arabia and other Middle East countries

## Summary
- Exclusive 5-year license to develop, market, and sell SOLOSEC in UAE, Kuwait, Saudi Arabia, Qatar and other Middle East countries.
- Pharma 1 targets mid-2025 regulatory submission in UAE; must file within 3 months of agreement.
- Consideration includes upfront payment, regulatory milestones, and sales-based milestones; supply at cost-plus.
- SOLOSEC is FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.
- Expands existing Evofem-Pharma 1 partnership beyond PHEXXI to SOLOSEC.

## SEC filing metadata
- accession: 0001641172-25-011962
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2025-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000164117225011962/0001641172-25-011962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000164117225011962/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-011962
- JSON: https://secwatch.observer/filing/0001641172-25-011962.json
- Plain text: https://secwatch.observer/filing/0001641172-25-011962.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.